Drug Trial Radar · NCT06993610
Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense
Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
247
Actual
Start
May 16, 2025
Primary completion
Sep 18, 2026
Study completion Apr 2027
Sponsor
- Lead sponsor
- Zura Bio IncIndustry
- Sponsor type
- Industry
- First posted
- May 29, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of tibulizumab over 16 weeks (Period 1) in adults with hidradenitis suppurativa, followed by a 16-week open-label extension period in which all participants will receive tibulizumab (Period 2)
Conditions
- Hidradenitis Suppurativa (HS)
Interventions
Tibulizumab Dose ABiological
Anti BAFF/IL-17 antibody. ZB-106
Tibulizumab Dose BBiological
Anti BAFF/IL-17 antibody. ZB-106
PlaceboOther
ZB-106 Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- [Period 1] Percent change from baseline in abscess and inflammatory nodule (AN) count at 16 weeksTime frame: Week 16
Locations
61 sites in 6 countries. Site status is shown where the registry gives one.
Medical Dermatology Specialists (Phoenix)
Phoenix, Arizona
First OC Dermatology Research, Inc.
Irvine, California
Wallace Medical Group, Inc.
Los Angeles, California
Northridge Clinical Trials
Northridge, California
NorCal Clinical Research
Rocklin, California
Florida Academic Dermatology Center
Coral Gables, Florida
Skin Care Research, LLC
Hollywood, Florida
Georgia Skin & Cancer Clinic
Savannah, Georgia
Indiana University School of Medicine
Indianapolis, Indiana
The Indiana Clinical Trials Center
Plainfield, Indiana
Equity Medical LLC (Kentucky)
Bowling Green, Kentucky
DS Research of Kentucky, LLC
Louisville, Kentucky
DelRicht LLC
Baton Rouge, Louisiana
Clinical Trials Management, LLC
Metairie, Louisiana
Beth Israel Deaconess Medical Center
Boston, Massachusetts
MediSearch Clinical Trials
Saint Joseph, Missouri
Skin Cancer and Dermatology Institute
Reno, Nevada
Equity Medical
New York, New York
OptiSkin Medical
New York, New York
Red River Research Partners
Fargo, North Dakota
Optima Research
Boardman, Ohio
ClinOhio Research Services
Columbus, Ohio
Apex Clinical Research Center
Mayfield Heights, Ohio
Best Skin Research LLC
Camp Hill, Pennsylvania
Palmetto Clinical Trial Services
Anderson, South Carolina
DelRicht Research
Mt. Pleasant, South Carolina
International Clinical Research - Tennessee LLC
Murfreesboro, Tennessee
Dermatology Treatment and Research Center
Dallas, Texas
BRCR Global Texas
Katy, Texas
DelRicht Research
Prosper, Texas
Progressive Clinical Research
San Antonio, Texas
Frontier Dermatology
Mill Creek, Washington
University of Washington Medical Center
Seattle, Washington
Dermatology Specialists of Spokane
Spokane, Washington
Ryan Clinical Research Inc.
Newmarket, Ontario, Canada
North York Research Inc
North York, Ontario, Canada
York Dermatology Clinic & Research Centre
Richmond Hill, Ontario, Canada
Centre de recherche Saint-Louis
Québec, Quebec, Canada
Saskatoon Dermatology Centre
Saskatoon, Saskatchewan, Canada
Fachklinik Bad Bentheim
Bad Bentheim, Germany
Showing 40 of 61 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.